Evidence map›Paper›PMID 40837601›Full record

ArticleImmunotherapy advances2025

Applying population mechanistic modelling to find determinants of chimeric antigen receptor T-cells dynamics in month-one lymphoma patients.

Liam V Brown, Mark McConnell, Robert Rosler, Leanne Peiser, Brian J Schmidt, Alexander V Ratushny, Eamonn A Gaffney, Mark C Coles

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in Immunotherapy advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02631044 (A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02631044 phase1completednot on this map

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

TypeinterventionalSponsorJuno Therapeutics, a Subsidiary of CelgeneRan2016 to 2024Enrolled387ConditionsNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell LymphomaArmsJCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Liam V BrownWolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, United Kingdom.
Mark McConnellChinook Therapeutics, Seattle, WA, United States.
Robert RoslerBristol Myers Squibb, Seattle, WA, United States.
Leanne PeiserBristol Myers Squibb, Seattle, WA, United States.
Brian J SchmidtBristol Myers Squibb, Princeton, NJ, United States.
Alexander V RatushnyBristol Myers Squibb, Seattle, WA, United States.
Eamonn A GaffneyWolfson Centre for Mathematical Biology, Mathematical Institute, University of Oxford, United Kingdom.ORCID https://orcid.org/0000-0002-6888-4362
Mark C ColesKennedy Institute of Rheumatology, University of Oxford, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chimeric antigen receptor (CAR) T-cells have been utilized for the treatment of several malignancies, including Non-Hodgkin lymphomas. A myriad of product- and patient-specific factors determines the extent of patient response, and determining which are most impactful requires analysis of clinical data. Methods: We used population-level ordinary differential equation models to fit clinical flow cytometry and tumour biopsy data from the TRANSCEND-NHL-001 (NCT02631044) study [1]. We analyzed the impact of lymphodepletion, CAR T-cell phenotypes, and other factors on CAR T-cell dynamics for 30 days after infusion. Results: We quantified the relative contribution of antigen-dependent and independent sources of proliferation on CAR T-cell dynamics, finding that both make a large contribution and that antigen-independent proliferation was highly correlated with patient IL-15 and IL-7 blood concentrations. The proportion of CAR T-cells in naïve, memory, or effector cells was found to have a limited impact on CAR T-cell dynamics, compared with lymphodepletion and tumour burden. Conclusions: This study shows how models can be used to link endogenous T-cells, CAR T-cells, and their phenotypes, and may be useful for determining whether a given patient may be responding poorly to treatment, by observing the dynamics of their endogenous T-cells. The framework we developed can be utilized for other CAR T constructs and indications, to test product alterations or biological hypotheses at the population level.

Indexed as

chimeric antigen receptorclinical trialslymphodepletionmodellingsimulation

Identifiers

PMID40837601
PMCPMC12362351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.